Alexander Hardy
Alexander Hardy serves as President and Chief Executive Officer of BioMarin and a member of the company’s Board of Directors.
Alexander joined BioMarin in December 2023 after more than 30 years in the global biopharmaceutical industry. Prior to BioMarin, he spent nearly 20 years at Genentech and Roche, most recently serving as chief executive officer of Genentech. During his time as Genentech’s CEO, he oversaw the successful launch of 10 innovative medicines and spearheaded the company’s entrance into several new therapeutic areas. Prior to that, Alexander led Roche’s Global Product Strategy organization and before that served as head of Asia Pacific for Roche. Earlier in his career, Alexander held a number of international leadership roles at Novartis. Alexander serves on the Board of Directors for the Pharmaceutical Research and Manufacturers of America (PhRMA).
Throughout his career, Alexander has championed a vibrant company culture that inspires employees to improve human health. He is an advocate for diversity, equity and inclusion to promote belonging within organizations and advance inclusive research across the biopharmaceutical industry.
Alexander completed his undergraduate education at University of Cambridge in the UK and earned his M.B.A. at the University of Michigan’s Ross School of Business. He lives in the San Francisco Bay Area with his wife and three daughters.
Henry J. Fuchs
Henry J. Fuchs, M.D. joined BioMarin in March 2009 and currently serves as our President of Worldwide Research & Development. From December 2009 to October 2016, Hank served as our Executive Vice President and Chief Medical Officer. From March 2009 to December 2009, Hank served as our Senior Vice President and Chief Medical Officer.
From September 2005 until December 2008, Hank served as Executive Vice President and Chief Medical Officer for Onyx Pharmaceuticals Inc., a biopharmaceutical company. Hank served as CEO of Ardea Biosciences, Inc. from January 2003 until June 2005. Hank first joined Ardea Biosciences, Inc. as Vice President, Clinical Affairs in October 1996 and was appointed President and Chief Operating Officer in November 2001. From 1987 to 1996, Hank held various positions at Genentech, Inc. where, among other responsibilities, he led the clinical program that resulted in the approval of Pulmozyme, a therapeutic for cystic fibrosis. Hank was also responsible for the Phase III development program that led to the approval of Herceptin to treat metastatic breast cancer.
Hank received an M.D. from George Washington University and a B.A. in biochemical sciences from Harvard University. Hank previously served as a director of Mirati Therapeutics, Inc., a public biopharmaceutical company, and was formerly on the board of Genomic Health, Inc., a public molecular diagnostics company, until its acquisition by Exact Sciences in November 2019.
Cristin Hubbard
Cristin Hubbard serves as Executive Vice President and Chief Commercial Officer, leading the company’s global commercial operations.
Cristin joined BioMarin in May 2024 following more than 20 years in the biopharmaceutical and diagnostics industries. She was most recently head of Global Product Strategy for Roche Pharma, where she was responsible for lifecycle management, accelerating delivery of the company’s medicines from development to commercialization, across five therapeutic areas. Over 16 years at Roche and Genentech, she served in a number of leadership positions across both organizations. Cristin started her career as a medicinal chemist at Theravance.
She holds a bachelor’s degree in Biochemistry and Molecular Biology from the University of California, Santa Cruz. She also completed the Graduate Program of Health Management at the University of California, Berkeley, earning an MBA from the Haas School of Business and an MPH from the School of Public Health.
Cristin lives in Marin County, where she enjoys spending time with her family and friends, and being outdoors as much as possible.
Brian R. Mueller
Brian R. Mueller joined BioMarin in December 2002 and currently serves as Executive Vice President and Chief Financial Officer and from March 2011 to June 2020 he served as Chief Accounting Officer. Prior to his role as Chief Accounting Officer, Brian served in accounting roles of increasing responsibility, including Corporate Controller.
Prior to joining BioMarin in 2002, Brian worked for KPMG as a senior manager in the firm’s audit practice. Brian joined KPMG after Arthur Andersen LLP ceased operations in June 2002, prior to which he spent seven years with Arthur Andersen LLP in the firm’s audit and business advisory services practice.
Brian holds a B.S. in Accountancy from Northern Illinois University in DeKalb, Illinois, and is a member of the American Institute of Certified Public Accountants.